Article
Marinus execs herald the rebirth of the one-drug biotech as a positive PhIII readout arrives for a
Rating:
0.0
Views:
124
Likes:
1
Library:
1
After a long, neck-snapping ride full of spills, thrills and dismal chills, the execs now running small-cap biotech Marinus $MRNS say they have achieved a signal success in a Phase III study of ganaxolone. Their sole drug, a GABA/A receptor modulator used as an anti-seizure drug — which has suffered
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value